FDA updates supply chain guidance for GLP-1 compounding pharmacies
New restrictions on wholesale bulk peptide ingredients aim to stabilize market quality standards and clarify the boundary between approved and compounded products.
Market Snapshot
“The next 18 months will define the standard of care for obesity for the next decade.”
— Dr. Elias Vance, Senior Editor
Recent Intelligence
View All News →Tirzepatide long-term cardiovascular outcomes show 15% risk reduction
SURMOUNT-CV trial results presented at a metabolic health summit exceeded initial analyst projections for major adverse cardiovascular event reduction.
Phase II data for oral GLP-1 alternatives shows promising bioavailability
A next-generation oral peptide formulation achieved bioavailability approaching that of injectable analogs without SNAC absorption enhancers.
Tirzepatide production scaling via new European bioreactor facilities
Three new bioreactors scheduled to come online in Ireland by Q1 aim to close the gap between soaring demand and finite peptide synthesis capacity.
Retatrutide Phase III program enrolls first patients in TRIUMPH cohort
The triple-agonist program advances into pivotal trials, setting up a potential head-to-head with dual agonists on the obesity standard of care.
Sector M&A volume climbs to $42.8B YTD on peptide dealmaking
Licensing activity around next-generation multi-receptor agonists drove a record quarter for GLP-1 and peptide therapeutic transactions.